On 12 Nov 2026 Edwards Lifesciences closed at $105.80, +24.1% this year; market cap $61.11bn, P/E 59.8.
Health Care · Health Care Equipment · NYSE · United States
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Market cap | $61.11bn |
| P/E (trailing) | 59.8 |
| EPS (TTM) | $1.77 |
| Beta | 0.83 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 4 Nov 2026 |
| Next earnings | 4 Feb 2027 |
| YTD | +24.1% |
| 1Y | +23.6% |
| 3Y | +17.9% |
| 5Y | -1.8% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $6.07bn | $1.07bn | $1.33bn |
| 2024 | $5.44bn | $4.17bn | $289.90m |
| 2023 | $6.00bn | $1.40bn | $629.50m |
| 2022 | $5.38bn | $1.52bn | $953.40m |
| 2021 | $5.23bn | $1.50bn | $1.40bn |
Base value $92.43 (-12.6% vs price); 0 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.